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Background: In cancer patients where gastrointestinal function is marginal and malnutrition significant enough to
result in the requirement for intensive nutrition support, parenteral nutrition (PN) is indicated. This longitudinal study
examined the quality of life (QoL) and nutritional outcomes in advanced cancer patients receiving home PN (HPN).
Methods: Fifty-two adult cancer patients (21 males, 31 females, average age 53 years) treated at a specialized cancer
facility between April 2009 and November 2011 met criteria. QoL and nutritional status were measured at baseline and
every month while on HPN using EORTC-QLQ-C30, Karnofsky Performance Status (KPS), and Subjective Global Assessment
(SGA). Repeated measures ANOVA and Generalized Estimating Equations (GEE) were used to evaluate longitudinal
changes in QoL and SGA.
Results: Cancer diagnoses included pancreatic (n = 14), colorectal (n = 11), ovarian (n = 6), appendix (n = 5), stomach
(n = 4) and others (n = 12). Average weight loss 6-months prior to HPN was 13.2 kg (16.9%). Average weight at
initiation of HPN was 62.2 kg. In patients with available follow-up data after 1 month (n = 39), there was a significant
improvement in SGA, weight (61.5 to 63.1 kg; p = 0.03) and KPS (61.6 to 67.3; p = 0.01) from baseline. Similarly, after
2 months (n = 22), there was an improvement in global QoL (37.1 to 49.2; p = 0.02), SGA, weight (57.6 to 60 kg; p = 0.04)
and KPS (63.2 to 73.2; p = 0.01) from baseline. Finally, after 3 months (n = 15), there was an improvement in global QoL
(30.6 to 54.4; p = 0.02), SGA, weight (61.1 to 65.9 kg; p = 0.04) and KPS (64.0 to 78.7; p = 0.002) from baseline. Upon GEE
analysis, every 1 month of HPN was associated with an increase of 6.3 points in global QoL (p<0.001), 1.3 kg in weight
(p = 0.009) and 5.8 points in KPS (p<0.001).
Conclusions: HPN is associated with an improvement in QoL, KPS and nutritional status in advanced cancer patients,
irrespective of their tumor type, who have compromised enteral intake and malnutrition. The greatest benefit was seen
in patients with 3 months of HPN, although patients receiving HPN for 1 or 2 months also demonstrated
significant improvements.
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Malnutrition is observed in up to 80% of patients with
advanced cancer [1-5]. Decreased dietary intake, cancer
cachexia (characterized mainly by weight loss and muscle
wasting), and nutrition impact symptoms may all contrib-
ute to cancer-related malnutrition [6]. Additionally, the
treatment modalities involving combinations of chemother-
apeutic, radiotherapeutic and surgical regimens are known* Correspondence: digant.gupta@ctca-hope.com
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unless otherwise stated.to produce various acute and chronic symptoms that limit
eating and, thereby, exert a profound impact on nutritional
status [7,8]. As a result, identifying and treating malnutri-
tion early in the course of advanced cancer is critical to
achieving favorable patient outcomes.
However, when malnutrition is significant enough to
result in the requirement for intensive nutrition support
in patients with marginal gastrointestinal (GI) function,
parenteral nutrition (PN) is indicated. Advanced cancer
patients with poor GI function and inadequate or inabil-
ity to take oral or enteral nutrition may receive PN withtd. This is an Open Access article distributed under the terms of the Creative
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porting them while they receive anti-cancer therapy,
which may also have a positive impact on survival
[9,10]. The success of PN depends on patient compli-
ance, the intensive consulting and support of all patients
and their relatives by a professional and committed nu-
tritionist, and the constructive cooperation between the
patient, the nutritionist, the supervising physician and the
home care provider [9]. As patients receive their treat-
ments outside the hospital, PN may be continued at home
(HPN) as an important adjuvant therapy.
While the administration of HPN has been shown to
improve survival in advanced cancer patients [10-13],
relatively little is known about the potential quality of
life (QoL) benefits of HPN [9,14,15]. Of particular men-
tion is the study by Bozzetti et al. who evaluated QoL
using the Rotterdam Symptom Checklist questionnaire
in advanced cancer patients on HPN and concluded that
patients who survive for longer than 3 months have time
to benefit in terms of QoL. They further suggested that
HPN should only be administered to patients with a
Karnofsky Performance Status (KPS) score greater than
50 [16]. While the study by Bozzetti et al. provides useful
insights on the QoL benefits of HPN, no studies have sys-
tematically documented monthly changes in QoL, nutri-
tional and functional status in advanced cancer patients
while receiving HPN.
In this study, we longitudinally investigated the QoL,
nutritional and functional outcomes of advanced can-




This was a longitudinal non-randomized clinical study
of 52 adult cancer patients treated at Cancer Treatment
Centers of America® (CTCA) located in Zion, IL,
Philadelphia, PA and Tulsa, OK between April 2009 and
November 2011 who were followed until March 2014.
The inclusion criteria for participation in this study were
a histologically confirmed diagnosis of cancer, antici-
pated survival of >90 days, no HPN therapy prior to
hospital admission, and no associated liver and kidney
problems. All patients had significant cancer cachexia
with tumor burden involving multiple organs and com-
promised GI function such that PN was the only option
for fulfilling their protein and caloric needs. Patients
who did not give informed consent or refused to partici-
pate were excluded from the study. All patients were
assured that refusal to participate would not affect their
future care in any way.
Patients who chose to participate underwent QoL and
nutritional status assessments at baseline and every
month while on HPN. All patients underwent activechemotherapy, radiation, or hormonal therapy while en-
rolled in the study. The treatment regimens were de-
cided by the oncologist of the patients based on the
National Comprehensive Cancer Network guidelines
when available. All patients received HPN from one na-
tional home infusion provider for consistency in therapy
delivery and management. In addition, Registered Dieti-
tians (RD) from the home infusion provider communi-
cated monthly with patients, while at home, to obtain
study data. Consistent training and education was com-
pleted at each participating CTCA site and serving
branch of the home infusion provider. This study was
approved by the Institutional Review Board at CTCA.
Home parenteral nutrition
Patients who were candidates for HPN were identified
by the Nutrition and Metabolic Support Team (NMST).
All patients in the study received a minimum of one
month of HPN from one national home infusion pro-
vider. PN was indicated following the American Society
of Parenteral and Enteral Nutrition (ASPEN) guidelines
in that each patient satisfied one or more of the follow-
ing: compromised GI function, enteral feeding not an
option, poor oral intake and moderately or severely mal-
nourished status [17]. All patients were given a daily cyc-
lic infusion. Patients’ calorie and protein needs were
estimated using the ASPEN guidelines for critical care.
Calorie needs were estimated using 25–30 kcal/kg for
BMI <30 and 22–25 kcal/kg of ideal body weight if
BMI > =30. Protein needs were estimated using 1.5 to
2 g/kg for BMI < 30 and 2 to 2.5 g/kg of ideal body
weight if BMI > =30. If patients had oral intake, the RD
estimated calorie and protein obtained and subtracted
that from total needs to determine the amount of calo-
ries and protein to be provided by HPN. Patients
received a Total Nutrient Admixture solution. Calories
from lipids were limited to < 30% of total daily require-
ment. Amino acids were added to meet estimated pro-
tein needs, and the remaining calories were provided by
dextrose. Most patients received Multivitamin Infusion-
13 with Vitamin K, unless contraindicated, and Multi-
trace 5, which includes selenium, zinc, copper, manga-
nese and chromium. Patients and at least one caregiver
were trained by a home health nurse on how to infuse
the HPN. After training, patients or their caregiver
infused the HPN. The home infusion provider moni-
tored compliance and response to therapy, and provided
a weekly clinical summary to the NMST. Inventory of
HPN bags and supplies was also conducted by the home
infusion provider and shared with the NMST. Patients
were monitored by NMST closely for their nutritional
status and recovery of GI function. Adjustments were
made to the macronutrient composition of the HPN if
oral intake changed significantly. HPN was stopped if
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qualified for continuation of HPN due to metabolic
complication or change in the clinical condition including
stopping all aggressive therapies. If patients were able
to consume approximately 65% of their estimated
calorie needs by mouth or enteral route, they were
weaned from HPN.
Quality of Life and Functional Status Assessment
QoL was assessed at baseline and every month while on
HPN using the European Organization for the Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC-QLQ-C30). The EORTC QLQ-C30 is a 30-
item cancer-specific questionnaire that incorporates 5
functioning scales (physical, role, cognition, emotional,
and social), 8 symptom scales (fatigue, pain, nausea/
vomiting, dyspnea, insomnia, loss of appetite, constipa-
tion, diarrhea), financial well-being scale and a global
scale (based on 2 items: “How would you rate your over-
all health during the past week?” and “How would you
rate your overall quality of life during the past week?”).
The raw scores are linearly transformed to give standard
scores in the range of 0 to 100 for each of the function-
ing and symptom scales. Higher scores in the global and
functioning scales and lower scores in the symptom
scales indicate better QoL. A difference of 5 to 10 points
in the scores represents a small change, 10 to 20 points
a moderate change, and greater than 20 points a large
clinically significant change from the patient’s perspec-
tive [18]. This instrument has been extensively tested for
reliability and validity [19-21]. Functional status was
measured using KPS and was determined by the man-
aging clinician. KPS was measured on a scale of 0 to 100
where 0 is dead and 100 is normal health with no evi-
dence of disease.
Nutritional assessment
All patients in the study were evaluated by an RD. Sub-
jective Global Assessment (SGA) was used to assess nu-
tritional status. The SGA is a clinical technique that
combines data from subjective and objective aspects of
medical history (weight change, dietary intake change,
gastrointestinal symptoms, and changes in functional
capacity) and physical examination (loss of subcutaneous
fat, muscle wasting, ankle or sacral edema and ascites).
After evaluation, patients are categorized into three
distinct classes of nutritional status; well nourished
(SGA-A), moderately malnourished (SGA-B) and se-
verely malnourished (SGA-C) as described by Detsky
et al. [22]. The SGA has been validated in a number of
diverse patient populations, including cancer patients
[23-27]. It has also been correlated with a number of
objective nutritional assessment indicators, morbidity,
mortality, and QoL measures [1,28-33]. At the subjects’first visit, measurement of height and weight were
performed. The subjects wore light clothing and no
shoes. Weight and serum albumin were also measured
at baseline and every month while on HPN.Statistical analysis
The primary outcome of interest was QoL (EORTC-
QLQ-C30). The secondary outcomes of interest were
nutritional status (SGA, serum albumin and weight),
performance status (KPS) and survival. Duration of
HPN was calculated as the number of days the patient
remained on HPN starting from the date of HPN start.
A comparison of baseline characteristics was made be-
tween patients with at least 3 months of follow-up data
and those with less than 3 months of follow-up data
using 2-sample t test or chi-square test depending upon
the underlying distribution of the variables.
As part of the initial longitudinal analyses, QoL, nu-
tritional status and performance status were analyzed
in three different groups of patients (those with at least
1, 2, or 3 months of follow-up data) using one-way re-
peated measures ANOVA with polynomial contrasts.
Mauchly’s test of sphericity (compound symmetry) was
evaluated and if found to be violated, Greenhouse-
Geisser epsilon adjustment was employed. Generalized
Estimating Equations (GEE) were then used to analyze
the longitudinal changes in 3 dependent variables: QoL
(as measured using EORTC-QLQ-C30), performance
status (as measured using KPS) and nutritional status
(as measured using weight and serum albumin). SGA
being a categorical variable was not included as a
dependent variable in the longitudinal GEE analyses. The
GEE procedure extends the generalized linear model to
allow for analysis of repeated measurements [34]. GEE
analyses do not require a balanced design (i.e., observations
at all measurements for each participant), and they
accommodate correlated errors due to repeated mea-
sures [35]. Unlike repeated measures ANOVA, GEE
does not discard all results on a subject with even a
single repeated measurement. In addition, GEE allows for
a wide variety of correlation structures to be explicitly
modeled and is more interpretable that repeated measures
ANOVA. Overall survival was defined as the time interval
between the date of HPN start and the date of patient’s
death from any cause or the date of last contact/last
known to be alive. The overall survival was calculated
using the Kaplan-Meier method. Log rank test for
used to evaluate the equality of survival distribution
across groups.
All data were analyzed using IBM SPSS version 20.0
(IBM, Armonk, NY, USA). All analyses were two-tailed,
and a difference was considered to be statistically significant
if the p value was less than or equal to 0.05.
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Patient characteristics
Table 1 describes the baseline characteristics of our pa-
tient cohort. Tables 2 and 3 compare the baseline char-
acteristics and QoL and nutritional scores respectively of
HPN patients available for 3 months or more versus
those with less than 3 months of follow-up. Thirty-seven
patients had less than 3 months of follow-up while 15
had 3 or more months of follow-up. Table 2 displays no
significant differences in the baseline characteristics be-
tween the 2 groups. Similarly, Table 3 demonstrates no
significant differences in QoL and nutritional status at
baseline between the two patient populations. However,
there was a significantly greater PN kcal (p = 0.04) and
PN protein (p = 0.03) intake in patients with less than
3 months of follow-up compared to those with 3 or
more months of follow-up. This finding is not surprising
because a majority of patients with less than 3 months
of follow-up had expired within 3 months and theirTable 1 Baseline patient characteristics (N = 52)
Characteristic Categories Number
(%)
Gender •Males 21 (40.4)
•Females 31 (59.6)
Class of Case •Analytic 24 (46.2)
•Non-analytic 28 (53.8)



















Age at HPN Start (years) 53.2 (9.4)
HPN duration (months) 3.4 (2.5)
Actual weight (Kg) 62.2 (14.6)
Percent weight loss 6-months prior to
HPN start (percent)
16.9 (9.3)
Albumin (g/DL) 2.9 (0.62)
Karnofsky Performance Status (KPS) 60.1 (10.8)mode of nutrition was primarily parenteral. On the other
hand, patients with 3 or more months of follow-up were
gradually moved from parenteral to enteral nutrition as
their condition improved. Finally, there was no significant
difference in the actual enteral intake between the two
groups.
The reasons for discontinuation of HPN in 37 patients
before the end of the 90-day study period were ascertained.
They were death or hospice (n = 23), change of home care
companies (n = 4), refusal to continue HPN (n = 3), elevated
liver function tests (n = 2), advanced to tube feeding (n = 2),
sepsis (n = 2) and tolerating adequate oral calorie and pro-
tein intake (n = 1). The mean duration of HPN was
3.4 months with a range of 0.4 to 11.7 months. A total of 9
patients received HPN for greater than equal to 9 months.
Of these 9 patients, only 1 patient developed a long-term
complication of hepatic dysfunction.
QoL and functional status
Table 4 describes the changes in KPS and QoL during
HPN using repeated measures ANOVA. Three differentTable 2 Comparison of baseline characteristics of HPN
patients available for 3-month follow-up versus those
available for less than 3-month follow-up






3 or months of
follow-up (N = 15)
P
Gender •Males 15 (40.5) 6 (40.0) 0.97
•Females 22 (59.5) 9 (60.0)
Class of Case •Analytic 17 (45.9) 7 (46.7) 0.96
•Non-analytic 20 (54.1) 8 (53.3)
Cancer Site •Pancreas 9 (24.3) 5 (33.3) 0.29
•Colorectal 9 (24.3) 2 (13.3)
•Ovarian 4 (10.8) 2 (13.3)
•Appendix 4 (10.8) 1 (6.7)
•Stomach 1 (2.7) 3 (20.0)
•Others 10 (27.0) 2 (13.3)
Stage at
Diagnosis
•1 2 (5.9) 1 (7.7) 0.94
•2 8 (23.5) 3 (23.1)
•3 8 (23.5) 4 (30.8)
•4 16 (47.1) 5 (38.5)
SGA •Moderately
Malnourished
15 (40.5) 4 (26.7) 0.35
•Severely
Malnourished
22 (59.5) 11 (73.3)
Age at HPN
Start (years)
•Mean 54.1 51.0 0.30
Values in table are numbers.
Values in parentheses are column percentages.
*P < = 0.05.
2-sample t test or chi-square test used to analyze the data.
Table 3 Comparison of nutritional and QoL scores of HPN
patients available for 3-month follow-up versus those
available for less than 3-month follow-up
Characteristic Patients with less
than 3 months of
follow-up (N = 37)
Patients with
3 or months of
follow-up (N = 15)
P
Nutritional Status
Actual weight (Kg) 62.7 (14.4) 61.1 (15.4) 0.72
Percent weight loss 6-
months prior to HPN
start (percent)
16.4 (8.7) 18.1 (10.8) 0.55
Albumin (g/DL) 2.9 (0.59) 2.9 (0.69) 0.66
Performance Status
KPS 58.6 (10.5) 64.0 (11.2) 0.11
QLQ-C30
General QoL
Global 38.1 (23.4) 30.1 (15.9) 0.26
General Function
Physical 53.7 (23.6) 55.5 (25.6) 0.80
Role 21.2 (19.9) 33.3 (32.7) 0.11
Emotional 58.5 (29.5) 59.4 (21.8) 0.92
Cognitive 64.9 (31.1) 64.4 (28.8) 0.96
Social 36.9 (29.4) 37.8 (33.0) 0.93
General Symptom
Fatigue 70.9 (22.3) 71.8 (23.3) 0.89
Nausea/Vomiting 56.7 (34.6) 45.5 (31.1) 0.28
Pain 54.5 (35.9) 48.9 (38.0) 0.62
Dyspnea 27.9 (30.9) 31.1 (29.4) 0.73
Insomnia 48.6 (31.0) 51.1 (41.5) 0.81
Appetite Loss 73.0 (28.1) 64.4 (32.0) 0.35
Constipation 34.2 (36.4) 40.0 (42.2) 0.62
Diarrhea 30.6 (33.7) 24.4 (36.6) 0.56
Financial Problems 44.1 (38.5) 53.3 (41.4) 0.50
Actual PN Intake
Kcal (per day) 1468.3 (328.0) 1273.2 (238.4) 0.04*
Protein (grams/day) 81.1 (16.4) 70.0 (14.6) 0.03*
Actual Enteral intake
Kcal (per day) 430.7 (703.0) 581.3 (990.7) 0.54
Protein (grams/day) 13.1 (16.6) 10.3 (10.1) 0.55
Values in table are means.
Values in parentheses are standard deviations.
*P < = 0.05.
QoL scores range from 0 to 100 and have no units.
2-sample t test used to analyze the data.
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of months of available follow-up data. The number of
patients available for 1, 2 and 3 months of follow-up
were 39, 22, and 15 respectively. After one month of
HPN (n = 39) there was a significant improvement in
KPS (61.6 to 67.3; p = 0.01), role function (26.4 to 46.7;p = 0.001), fatigue (71 to 59.2; p = 0.03), nausea/vomiting
(52.3 to 37; p = 0.03), appetite loss (67.6 to 46.3; p = 0.004)
and constipation (37 to 22.2; p = 0.03). After 2 months of
HPN (n = 22), there was a significant improvement in KPS
(63.2 to 73.2; p = 0.01), global QoL (37.1 to 49.2; p = 0.02),
physical function (56.4 to 70.1; p = 0.02), role function
(29.5 to 55.3; p = 0.01), emotional function (58.7 to 72.3;
p = 0.03), fatigue (73.2 to 50.5; p = 0.002) and appetite
loss (68.2 to 33.3; p = 0.001). After 3 months (n = 15),
there was a significant improvement in KPS (64.0 to
78.7; p = 0.002), global QoL (30.6 to 54.4; p = 0.02),
physical function (55.6 to 72; p = 0.04), role function
(33.3 to 58.9; p = 0.03), fatigue (71.8 to 43.7; p = 0.01),
appetite loss (64.4 to 33.3; p = 0.02) and constipation
(40 to 8.9; p = 0.05). Upon univariate GEE analysis
(Table 5), every 1 month of HPN was associated with a
significant improvement in KPS by 5.8 points (p < 0.001),
global QoL by 6.3 points (p < 0.001), physical QoL by 5.8
points (p = 0.005), role QoL by 12.2 points (p < 0.001),
emotional QoL by 4.8 points (p = 0.008), social QoL
by 6.2 points (p = 0.04), fatigue by 9.1 points (p < 0.001),
nausea/vomiting by 7.1 points (p = 0.005), pain by 6.7
points (p = 0.008), insomnia by 6.5 points (p = 0.02),
appetite loss by 13.7 points (p < 0.001) and constipation
by 8.8 points (p < 0.001). These improvements remained
significant after controlling for age, gender and treatment
history.
Nutritional status
At baseline (n = 52), 19 (36.5%) patients were SGA-B and 33
(63.5%) were SGA-C. After 1 month of HPN (n = 39), 2
(5.1%) were SGA-A, 20 (51.3%) were SGA-B and 17 (43.6%)
were SGA-C. After 2 months of HPN (n = 22), 3 (13.6%)
were SGA-A, 13 (59.1%) were SGA-B and 6 (27.3%) were
SGA-C. After 3 months of HPN (n = 15), 2 (13.3%) were
SGA-A, 12 (80%) were SGA-B and 1 (6.7%) was SGA-C.
The improvements in SGA were statistically significant
(p < 0.05) at all time points. Table 4 describes the changes
in other nutritional parameters (weight and albumin) dur-
ing HPN using repeated measures ANOVA. After one
month of HPN (n = 39) there was a significant improve-
ment in weight (61.5 to 63.1 kg; p = 0.03) and albumin (2.8
to 3.1 g/dl; p = 0.03). After 2 months of HPN (n = 22), there
was a significant improvement in weight (57.6 to 60 kg; p =
0.04). After 3 months (n = 15), there was a significant
improvement in weight (61.1 to 65.9 kg; p = 0.04). Upon
univariate GEE analysis (Table 5), every 1 month of HPN
was associated with a significant improvement in weight by
1.3 kg (p = 0.009). These improvements remained signifi-
cant after controlling for age, gender and treatment history.
Survival analysis
At the time of this analysis (March 2014), 48 (92.3%)
patients had expired. On Kaplan-Meier analysis, median
Table 4 Changes in nutritional and QoL parameters during HPN
Characteristic Baseline Month 1 P Baseline Month 1 Month 2 P Baseline Month 1 Month 2 Month 3 P
N = 39 N = 22 N = 15
Nutritional Status
Weight (Kg) 61.5 (13.4) 63.1 (12.7) 0.03* 57.6 (14.1) 59.9 (13.8) 60.0 (12.4) 0.04* 61.1 (15.4) 63.4 (15.0) 63.6 (12.8) 65.9 (13.6) 0.04*
Albumin (g/DL) 2.8 (0.61) 3.1 (0.65) 0.03* 2.9 (0.66) 3.1 (0.59) 4.3 (5.1) 0.26 2.9 (0.69) 3.1 (0.65) 3.3 (0.44) 3.0 (0.57) 0.28
Performance Status
KPS 61.6 (11.2) 67.3 (10.7) 0.01* 63.2 (9.9) 70.0 (11.1) 73.2 (12.9) 0.01* 64.0 (11.2) 67.3 (11.0) 75.3 (14.6) 78.7 (11.2) 0.002*
QLQ-C30
General QoL
Global 38.6 (20.6) 46.3 (23.1) 0.98 37.1 (18.1) 51.5 (25.7) 49.2 (21.0) 0.02* 30.6 (15.9) 45.6 (27.1) 47.8 (23.4) 54.4 (24.8) 0.02*
General Function
Physical 59.6 (20.9) 62.4 (16.0) 0.39 56.4 (22.2) 66.1 (17.4) 70.1 (22.1) 0.02* 55.6 (25.6) 65.8 (20.1) 75.6 (23.2) 72.0 (21.8) 0.04*
Role 26.4 (25.3) 46.7 (33.1) 0.001* 29.5 (29.1) 49.2 (37.3) 55.3 (32.7) 0.01* 33.3 (32.7) 36.7 (36.3) 58.9 (31.1) 58.9 (39.8) 0.03*
Emotional 61.3 (22.8) 64.6 (26.3) 0.50 58.7 (22.9) 72.0 (24.5) 72.3 (25.9) 0.03* 59.4 (21.8) 67.2 (27.0) 67.2 (28.4) 72.8 (24.5) 0.19
Cognitive 65.7 (25.5) 68.1 (30.4) 0.57 66.7 (26.7) 73.5 (30.7) 77.3 (27.0) 0.10 64.4 (28.8) 67.8 (29.8) 78.9 (23.1) 64.4 (29.4) 0.09
Social 37.0 (27.6) 46.3 (29.6) 0.79 41.7 (32.8) 54.5 (30.9) 58.3 (27.1) 0.09 37.8 (33.0) 43.3 (27.3) 55.6 (30.6) 51.1 (34.2) 0.30
General Symptom
Fatigue 71.0 (20.8) 59.2 (26.8) 0.03* 73.2 (21.6) 54.0 (30.3) 50.5 (26.9) 0.002* 71.8 (23.3) 58.5 (34.2) 45.2 (28.3) 43.7 (30.1) 0.01*
Nausea/ 52.3 (29.3) 37.0 (31.9) 0.03* 47.7 (26.7) 43.9 (34.7) 36.4 (32.3) 0.30 45.5 (31.1) 48.9 (34.8) 31.1 (30.1) 34.4 (30.5) 0.20
Vomiting
Pain 51.4 (35.5) 44.0 (29.6) 0.16 46.2 (37.8) 36.4 (31.1) 28.0 (29.3) 0.06 48.9 (38.0) 35.5 (35.6) 27.8 (31.9) 32.2 (31.5) 0.12
Dyspnea 25.9 (27.7) 19.4 (23.0) 0.21 21.2 (28.2) 16.7 (22.4) 16.7 (26.7) 0.74 31.1 (29.4) 17.8 (21.3) 17.8 (27.8) 20.0 (30.3) 0.41
Insomnia 47.2 (32.2) 45.4 (37.5) 0.77 45.4 (37.9) 40.9 (37.0) 28.8 (27.8) 0.18 51.1 (41.5) 48.9 (37.5) 26.7 (28.7) 33.3 (33.3) 0.09
Appetite Loss 67.6 (29.3) 46.3 (38.4) 0.004* 68.2 (28.1) 39.4 (38.0) 33.3 (39.8) 0.001* 64.4 (32.0) 48.9 (39.6) 31.1 (36.6) 33.3 (37.8) 0.02*
Constipation 37.0 (38.3) 22.2 (31.9) 0.03* 33.3 (38.5) 25.7 (29.0) 24.2 (34.4) 0.43 40.0 (42.2) 33.3 (30.9) 22.2 (32.5) 8.9 (26.6) 0.05*
Diarrhea 33.3 (37.4) 25.9 (31.0) 0.25 31.8 (39.1) 21.2 (26.3) 24.2 (37.3) 0.51 24.4 (36.6) 13.3 (16.9) 24.4 (36.6) 26.7 (40.2) 0.58
Financial 47.2 (39.3) 38.9 (32.4) 0.07 48.5 (42.0) 36.4 (37.0) 39.4 (40.7) 0.14 53.3 (41.4) 40.0 (36.1) 37.8 (39.6) 53.3 (39.4) 0.18
Problems
Values in table are means.
Values in parentheses are standard deviations.
*P < = 0.05.
QoL scores range from 0 to 100 and have no units.
One-way repeated measures ANOVA used to analyze the data.
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http://www.biomedcentral.com/1471-2407/14/593overall survival for the entire patient cohort was
5.1 months (95% CI: 2.8-7.3 months). The median sur-
vival for “KPS < =50” patients and “KPS > 50” patients
was 6.4 and 4.6 months respectively, log-rank p = 0.25.
The median survival for “SGA-B” patients and “SGA-C”
patients was 3.2 and 6.5 months respectively, log-rank
p = 0.39. Twenty-seven patients survived greater than
6 months while 25 survived less than 6 months. There
were no statistically significant differences in the charac-
teristics of those 2 groups although patients surviving
less than 6 months had (as expected) more advanced
disease at diagnosis. Twelve patients survived greater
than 1 year, and of those 12, 5 patients survived greater
than 2 years. Of 5 patients surviving greater than 2 years
(mean age 53.2 years), 3 are still alive; 2 had colorectal, 2pancreatic and 1 ovarian cancer; 3 received 3 or more
months of HPN; 3 had baseline KPS > 50; 3 were base-
line SGA-C; 3 were females; and 3 were previously
treated before coming to our institution.
Discussion
To the best of our knowledge this is the first US-based
study to investigate QoL, nutritional status and func-
tional outcomes of advanced cancer patients receiving
HPN. We chose the EORTC QLQ-C30 as a valid and
reliable tool to assess patients’ QoL. The EORTC QLQ-
C30 concentrates on patients’ ability to fulfill the activ-
ities of daily life. Clinical practitioners and investigators
need to know what happens to a patients’ capacity to
fulfill the activities of daily life at work and at home.
Table 5 Longitudinal GEE analyses for QoL, nutritional and functional outcomes
Dependent
Variable
Univariate GEE β P-Value Multivariate GEE β P-Value
95% CI 95% CI
Nutritional Status
Weight (Kg) 1.3 (0.32 to 2.2) 0.009* 1.2 (0.27 to 2.2) 0.01
Albumin (g/DL) 0.26 (−0.12 to 0.6) 0.18 0.25 (−0.1 to 0.6) 0.17
Performance Status
KPS 5.8 (3.8 to 7.8) <0.001* 5.9 (4.0 to 7.8) <0.001*
QLQ-C30
General QoL
Global 6.3 (2.9 to 9.6) <0.001* 6.2 (2.7 to 9.6) <0.001*
General Function
Physical 5.8 (1.8 to 9.9) 0.005* 5.7 (1.7 to 9.8) 0.006*
Role 12.2 (5.9 to 18.4) <0.001* 12.1 (6.0 to 18.3) <0.001*
Emotional 4.8 (1.2 to 8.3) 0.008* 4.7 (1.1 to 8.3) 0.01*
Cognitive 1.2 (−2.5 to 4.8) 0.53 1.1 (−2.5 to 4.8) 0.54
Social 6.2 (0.2 to 12.3) 0.04* 6.2 (0.1 to 12.2) 0.04*
General Symptom
Fatigue −9.1 (−13.9 to −4.4) <0.001* −9.0 (−13.8 to −4.2) <0.001*
Nausea/ Vomiting −7.1 (−12.0 to −2.2) 0.005* −7.0 (−11.6 to −2.5) 0.002*
Pain −6.7 (−11.7 to −1.8) 0.008* −6.7 (−11.7 to −1.7) 0.009*
Dyspnea −3.7 (−9.6 to 2.2) 0.22 −3.6 (−9.6 to 2.3) 0.23
Insomnia −6.5 (−12.2 to −0.9) 0.02* −6.4 (−12.1 to −0.8) 0.02*
Appetite Loss −13.7 (−19.2 to −8.1) <0.001* −13.4 (−18.8 to −8.1) <0.001*
Constipation −8.8 (−13.8 to −3.7) 0.001* −8.7 (−13.6 to −3.7) 0.001*
Diarrhea −0.87 (−8.0 to 6.2) 0.81 −0.6 (−7.5 to 6.3) 0.86
Financial Problems −0.2 (−4.8 to 4.8) 0.99 −0.09 (−4.9 to 4.7) 0.97
GEE β estimates in the table above reflect changes in the dependent variable for every 1 month increase in time.
Multivariate β estimates were adjusted for age, gender and treatment history.
*P < =0.05.
QoL scores range from 0 to 100 and have no units.
Longitudinal Generalized Estimating Equations used to analyze the data.
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functioning scale coupled with a comprehensive symp-
tom inventory.
The key finding of our study was that HPN is associated
with an improvement in QoL, nutritional and functional
status in patients with advanced cancer having compro-
mised oral/enteral intake and malnutrition. The greatest
benefit in terms of QoL, nutritional and functional status
was seen in patients who underwent 3 months of HPN,
although patients receiving HPN for 1 or 2 months also
demonstrated significant improvements.
Few other studies have reported on QoL in patients
with advanced cancer on HPN. A study by Bozzetti in-
vestigated the changes of QoL in advanced cancer pa-
tients during HPN. The study concluded only patients
who survive longer than 3 months have enough time
to benefit – though only temporarily – in terms of QoL
[16]. The study also suggested that HPN be administeredto patients with a KPS >50 provided that the medical
indication is valid, that there is a positive assessment of
well-being, and that the HPN be continued for a 1 month
trial as long as there is no worsening of the patient’s
physical state [16]. Our study findings are similar, how-
ever, we demonstrated an improved QoL, nutritional
and functional status starting after one month of HPN
and documented improved nutritional status using SGA,
a validated tool measuring nutritional status. In addition,
we found that baseline KPS <50 was not associated
with a higher risk of death and those patients might
benefit from HPN as well. Therefore, we suggest that
HPN be administered to patients regardless of their
KPS scores.
The results of this study have important implications
for both clinical and research practices. They suggest
that HPN can be initiated in patients with advanced
cancer to improve QoL, nutritional status and functional
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http://www.biomedcentral.com/1471-2407/14/593status. Patient QoL is an extremely important outcome
measure for cancer patients. How patients feel, physic-
ally and emotionally, while they are fighting cancer can
have an enormous effect on their ability to carry out
normal daily functions as well as on their interpersonal
relationships and their ability to work. Routine QoL
measurements should be collected to assess the benefits
of HPN therapy. Our data show that after one month of
HPN therapy, QoL scores begin to improve and patients
begin to suffer less from appetite loss, constipation, nau-
sea/vomiting and fatigue. Role function begins to im-
prove along with SGA, weight and KPS Future research
should focus on devising the best management practices
for timing of nutritional assessment and intervention in
advanced cancer patients and testing their value in con-
trolled clinical studies.
Given that individuals cannot survive without nutrient
intake, the ability to perform at a level allowing normal
to semi-normal activity could not happen without HPN.
This allows oral intake to be for pleasure or comfort
(if tolerated) rather than it to be forced and measured.
Usual key clinical measures may not indicate progress
due to the presence of inflammation and the disease
process therefore potentially negating the positive out-
comes of HPN. However, a recent study by Culine et al.
indicated that not only QoL but weight, serum albumin
and nutrition risk improved significantly after one month
of HPN [36]. Perhaps more importantly, the family and
physicians managing these patients noticed the improve-
ment in well-being.
There are several limitations of this study that require
acknowledgement. The study has a relatively small sam-
ple size of 52 advanced cancer patients with no formal
sample size estimation carried out at the study outset.
This is due to the fact that the study was limited to a
specific population of cancer patients eligible for HPN
therapy. As a result, the generalizability of this study’s
findings might be limited. In addition, the study lost
some participants after each month of HPN therapy due
to death, hospice, tolerating adequate calorie and protein
intake and other reasons. Because of a relatively small
sample size of 52, it was not possible to comprehen-
sively evaluate the predictors of overall survival. How-
ever, survival was not the primary endpoint of the
study to begin with. Finally, the study lacks a control
group, which makes it difficult to make any definitive
conclusions about cause and effect. This study also has
several strengths including a longitudinal prospective
design, no missing data on any EORTC QLQ-C30 vari-
ables for the entire study sample; the use of a valid and
reliable QoL and nutritional assessment instrument;
and the availability of clinical data in nearly all pa-
tients. In addition, this study was done in patients re-
ceiving HPN in a typical home environment ratherthan in a research setting which allows direct applica-
tion to clinical care.
Conclusions
HPN is associated with an improvement in QoL, nutri-
tional status and functional in advanced cancer patients,
irrespective of their tumor type, who have compromised
enteral intake and malnutrition. The greatest benefit
was seen in patients with 3 months of HPN, although
patients receiving HPN for 1 or 2 months also demon-
strated significant improvements. When advanced cancer
patients cannot receive adequate nutrients enterally or or-
ally and anti-cancer therapy is continued, HPN is an im-
portant component of the care plan.
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